- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Ruth M.D. Byrne, K.C.
News 25 results
Recognition
March 31, 2023
King & Spalding Once Again Earns Top Spot on Global Arbitration Review’s GAR 30 Ranking
Recognition
February 16, 2023
King & Spalding Earns Strong Rankings in Chambers Global 2023 Results
In the News · Source: Law360
November 8, 2022
Ruth Byrne KC and Kabir Bhalla represent GW Pharma in a dispute involving unpaid royalties for a seizure treatment
Recognition
November 8, 2022
Legal 500 Names Tom Sprange KC to its International Arbitration Powerlist UK 2022
Recognition
October 20, 2022
King & Spalding Receives Multiple Rankings in Chambers UK 2023 Guide
Recognition
September 29, 2022
King & Spalding Earns Multiple Rankings in Legal 500 UK 2023 Guide
Cases & Deals
July 12, 2022
King & Spalding Supports JUSTICE Working Party On Hybrid Orders
Recognition
April 4, 2022
King & Spalding Named Top International Arbitration Practice Worldwide
Cases & Deals
February 28, 2022
King & Spalding advises JUSTICE on response to UK’s proposed human rights overhaul
Recognition
February 18, 2022
Chambers Global 2022 Recognizes King & Spalding as a Leading International Law Firm
Recognition
December 22, 2021
Ruth Byrne Appointed to Queen’s Counsel 2021 List
In the News · Source: Law.com International, The Global Legal Post, The Law Society Gazette, Legal Business, The Lawyer, Global Arbitration Review and Legal Era
December 22, 2021
Ruth Byrne has been appointed Queen’s Counsel in the 2021 QC list